Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Vascular responsiveness after muscle contraction to a single dose of tadalafil.
Timeframe: up to 4 weeks after the completion of Visits 1 and 2 of Aim 1.
Cycling time to fatigue
Timeframe: Baseline and 6 month follow-up visits of Aim 2.